TABLE 1.

Baseline characteristics of the patient.

	PVRP group (n = 11)	Control group (n = 11)	p
Gender
Male (n, %)	9 (82%)	9 (82%)	1.000
Female (n, %)	2 (18%)	2 (18%)
Age
M ± SD (years)	47 ± 18	52 ± 24	0.632‡
Comorbidities
Yes (n, %)	6 (55%)	6 (55%)	1.000
No (n, %)	5 (45%)	5 (45%)
Regular medicine intake
Yes (n, %)	3 (27%)	6 (55%)	0.387*
No (n, %)	8 (73%)	5 (45%)
Allergies
Yes (n, %)	5 (45%)	4 (36%)	1.000*
No (n, %)	6 (55%)	7 (64%)
Coagulopathy
Yes (n, %)	2 (18%)	1 (9%)	1.000*
No (n, %)	9 (82%)	10 (91%)
Smoking
Yes (n, %)	2 (18%)	5 (45%)	0.361*
No (n, %)	9 (82%)	6 (55%)
Alcohol consumption
Yes (n, %)	10 (91%)	7 (64%)	0.311*
No (n, %)	1 (9%)	4 (36%)
Time to treatment
Mdn (day–years)	2,688–7.4	3,172–8.7	0.116**
Time from surgery
Mdn (days–years)	4,644–12.7	5,224–14.3	0.573**
COMQ-12 score
Mdn	33	34	0.977**

Time to treatment – the time from the beginning of the problems due to chronic postoperative temporal bone cavity inflammation to the first checkup of the trial; time from surgery – the time from the last surgery required to treat chronic ear disease to the first checkup of the trial. PVRP: platelet- and extracellular vesicle-rich plasma; n: number of patients; M: average value; ^‡independent samples t-test; *Fisher’s exact test; Mdn: median value; **Mann–Whitney U-test; COMQ-12: chronic otitis media questionnaire 12; p-value < 0.05 denotes statistically significant difference. Coagulopathy occurred as a consequence of regular acetylsalicylic acid intake.